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Arabia.Antimicrobial resistance (AMR) is a global health
emergency, and experts are concerned that the
end of the age of antimicrobials is imminent
[1–6]. Since the introduction of antimicrobials
nearly a century ago, microbes have evolved a
variety of methods to resist these drugs. Today,
the world is dealing with ‘superbugs’ that are
virtually untreatable, including drug-resistant
gonorrhea, carbapenem-resistant enterobacteri-
aceae, Methicillin-resistant Staphylococcus aur-
eus, and extended-spectrum-beta-lactamase
producing strains [5]. The antibiotic pipeline is
running dry, and AMR is threatening to undo
major gains made in the control of infectious
diseases. Models suggest that 300 million people
are expected to die prematurely because of AMR
over the next 35 years and the world’s GDP will
be 2–3.5% lower than it otherwise would be in
2050 [6]. This translates into a loss of 60–100
trillion USD worth of economic output by 2050.
AMR is driven by several factors, but major
causes include over-use of antibiotics, poor adher-
ence to standard treatment schedules, over-use of
antibiotics in livestock, poor infection control in
hospitals, lack of hygiene, and challenges with
new antibiotic discovery [1,5].
Antibiotic consumption is increasing globally,
with 20-50% estimated to be inappropriate [5].
According to the State of the World’s Antibiotics
report (2015) [5], the countries consuming the
most antibiotics overall in 2010 were India, 13
billion standard units-squared [SU]; China, 10billion SU; and the United States, 7 billion SU.
However, in per capita terms among these coun-
tries, the United States led in 2010 with 22 SU
per person, compared with 11 SU in India and 7
SU in China [5].
Drug-resistant tuberculosis (DR-TB) is a good
example of AMR. The most common form of drug-
resistant TB is multi-drug resistant TB (MDR-TB),
which refers to TB that is resistant to isoniazid
and rifampicin. Globally in 2014, WHO estimated
3.3% of new cases and 20% of previously treated
cases to have MDR-TB [7]. Drug resistance surveil-
lance data show that an estimated 480,000 people
developed MDR-TB in 2014 and 190,000 people died
[7]. Extensively drug-resistant (XDR-TB) strains are
resistant to at least four of the core anti-TB drugs,
and XDR-TB has been reported by 105 countries in
2014. On average, an estimated 9.7% of people
with MDR-TB have XDR-TB [7]. Some studies have
also reported totally drug-resistant strains of TB
[8].
Why should we care about DR-TB? The answer is
straightforward. Drug-resistant TB requires exten-
sive treatment (for 2 years or longer) with multi-
ple, potentially toxic drugs and outcomes are
poor. About 50% of patients with drug-resistant
TB die because of it [9]. Treatment of DR-TB is also
very expensive because of the high cost of second-
line TB drugs. Thus, prevention of DR-TB is critical.
WHO has proposed 5 priority actions to tackle the
global DR-TB crisis: (1) prevent the development
of drug-resistance through high quality treatment
of drug-susceptible TB; (2) expand rapid testing
and detection of DR-TB cases; (3) provide immedi-
ate access to effective treatment and proper care;
(4) prevent transmission through infection control;
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ing [7].
Unfortunately, high TB burden countries are
yet to seriously address these priority actions to
tackle DR-TB. In many countries, less than 50%
of patients with DR-TB are on second-line drug
therapy [7]. Quality of TB care for even drug-sus-
ceptible TB remains suboptimal in many coun-
tries, especially in countries with large numbers
of private health care providers [10–12]. In such
settings, doctors prescribe irrational drug regi-
mens, and adherence monitoring is poor
[10,12]. Empirical antibiotic use is widespread
in many countries with weak regulation, and this
further increases the risk of AMR [13]. Also, over-
the-counter antibiotic abuse is widespread in
many high TB burden countries [5]. OTC use of
fluoroquinolones, a widely used antibiotic, can
delay the diagnosis of TB, and also increase the
risk of DR-TB [14]. This is particularly relevant,
since some of the emerging new TB drug regi-
mens contain fluoroquinolones.
While molecular tests such as Xpert MTB/RIF
(Cepheid Inc, Sunnyvale, CA, USA) are now avail-
able to rapidly detect drug-resistance, most high-
burden countries are still reliant on sputum smear
microscopy [15]. A recent report called ‘Out of
Step’ by Medicins sans Frontiers (MSF) and Stop
TB Partnership surveyed 24 high TB burden coun-
tries, to see how already existing TB policies and
interventions are being implemented [16]. This
study found major implementation gaps. For
example, only 8 countries included in the survey
had revised their national policies to include Xpert
MTB/RIF as the initial diagnostic test for all adults
and children with presumptive TB, replacing smear
microscopy. Six of 24 countries still recommended
intermittent treatment for drug-sensitive TB
(which is less effective than daily therapy). Even
simple interventions such as fixed dose combina-
tions to improve treatment adherence are not rou-
tinely used in all countries.
Clearly, TB is a low priority for many develop-
ing countries, and current investments are insuf-
ficient to make progress in addressing DR-TB. In
this context, it may be more impactful for DR-
TB control to be seen as one component of a
comprehensive strategy to address AMR. Unlike
TB, AMR is increasingly seen as a global health
emergency and a security threat [1,2,6]. Policy
makers and donor agencies have prioritized AMR
as a key issue for the global health security
agenda [1–6]. The door is wide open for the TBcommunity to leverage this interest, and advo-
cate for a well-funded AMR initiative that
includes DR-TB as a key component. To quote
Margaret Chan, ‘‘antimicrobial resistance is a cri-
sis that must be managed with the utmost
urgency. As the world enters the ambitious new
era of sustainable development, we cannot allow
hard-won gains for health to be eroded by the
failure of our mainstay medicines.” [1].
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